

1 March 2023

**ValiRx PLC ("ValiRx" or the "Company")**

**Investor Webinar**

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health announces that Dr Suzanne Dilly will be presenting a live investor webinar on Wednesday, 8 March 2023 at 17:30 GMT.

The presentation will concentrate on the Company's strategy for its new tCRO operations, including progress on setting up the dedicated lab facilities in Nottingham.

The live webinar, which will be hosted by the Company's Joint Broker, Turner Pope Investments, is open to existing and prospective investors. There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process. In addition, questions can be submitted during the live event.

To register for the webinar please visit the following link:

<https://vimeo.com/webinars/events/d731558a-ecb5-40f0-9d7b-415902d2dd1f>

The Directors of the Company take responsibility for this announcement.

**For further information, please contact:**

<b>ValiRx plc</b> Dr Suzanne Dilly, CEO	<b>Tel: +44 (0) 2476 796496</b> <a href="http://www.valirx.com">www.valirx.com</a> Suzanne.Dilly@valirx.com
<b>V Formation (Public Relations)</b> Lucy Wharton - Senior PR Executive Sue Carr - Director	<b>+44 (0) 115 787 0206</b> <a href="http://www.vformation.biz">www.vformation.biz</a> lucy@vformation.biz sue@vformation.biz
<b>Cenkos Securities Limited (Joint Broker)</b> Russell Kerr/Michael Johnson (Sales) Callum Davidson/Giles Balleny (Corporate Finance)	<b>Tel: +44 (0) 20 7397 8900</b>
<b>Turner Pope Investments (TPI) Limited (Joint Broker)</b> James Pope / Andy Thacker	<b>Tel: +44 (0) 20 3657 0050</b>

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRADGGDDSGDDGX1